<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ROBAXIN- methocarbamol injection, solution </strong><br>Baxter Healthcare Corporation<br></p></div>
<h1>ROBAXIN Injectable (methocarbamol injection, USP)<br>Rx only</h1>
<div class="Contents">
<div class="Section">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="INV-ff780ea1-c31d-4de1-9353-c10fa0b9e47f"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First"><a name="INV-06b69d7b-5e83-4e78-86cb-d433ef415fbe"></a>ROBAXIN (methocarbamol injection, USP) Injectable, a carbamate derivative of guaifenesin, is a central nervous system (CNS)
							depressant with sedative and musculoskeletal relaxant properties. It is a sterile, pyrogen-free solution intended for intramuscular or intravenous administration.</p>
<p><a name="INV-7ed4ba4d-2d86-46df-b9b0-e28f907fc1d2"></a>Each mL contains: methocarbamol, USP 100 mg, polyethylene glycol 300, NF 0.5 mL, Water for Injection, USP q.s. The pH is adjusted,
							when necessary, with hydrochloric acid and/or sodium hydroxide. The chemical name of methocarbamol is 3‑(2‑methoxyphenoxy)‑1,2-propanediol 1‑carbamate and has the empirical formula of
								C<span class="Sub">11</span>H<span class="Sub">15</span>NO<span class="Sub">5</span>. Its molecular weight is 241.24. The structural formula is shown below:</p>
<div class="Figure"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8f91e243-7395-4ec9-adf5-37520983daf2&amp;name=Robaxin_Injectable-Figure-1.jpg"></div>
<p><a name="INV-50c5fec3-8f16-4436-bcfe-4b31096d67d0"></a>Methocarbamol is a white powder, sparingly soluble in water and chloroform, soluble in alcohol (only with heating) and propylene
							glycol, and insoluble in benzene and <span class="Italics">n</span>‑hexane.</p>
<p><a name="INV-c139d32f-a606-4781-b715-bc1f0cbe15e8"></a>ROBAXIN Injectable has a pH between 3.5 and 6.0.</p>
<p><a name="INV-17133f85-b66b-47d4-b520-2fbd3d9b1270"></a>AFTER MIXING WITH I.V. INFUSION FLUIDS,<span class="Bold"> DO NOT REFRIGERATE.</span></p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="INV-8bb2c70e-08c5-46e9-80b1-157c765193a4"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First"><a name="INV-13d136e7-33dd-4c85-a035-f2f2522c5225"></a>The mechanism of action of methocarbamol in humans has not been established, but may be due to general <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>. It has no
							direct action on the contractile mechanism of striated muscle, the motor end plate or the nerve fiber.</p>
<div class="Section">
<a name="INV-7bbfb1eb-9b56-4a2d-aaf6-62989d4fc5c4"></a><a name="section-3.1"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First"><a name="INV-cdb5dd62-8729-4db5-9e95-74c3d229095b"></a>In healthy volunteers, the plasma clearance of methocarbamol ranges between 0.20 and 0.80 L/h/kg, the mean plasma elimination
									half-life ranges between 1 and 2 hours, and the plasma protein binding ranges between 46% and 50%.</p>
<p><a name="INV-062311a9-fed0-4562-8b2a-832001b19f04"></a>Methocarbamol is metabolized via dealkylation and hydroxylation. Conjugation of methocarbamol also is likely. Essentially all
									methocarbamol metabolites are eliminated in the urine. Small amounts of unchanged methocarbamol also are excreted in the urine.</p>
<div class="Section">
<a name="INV-f48d2f7a-3a25-4aa8-81d0-ef801cf02f5e"></a><a name="section-3.1.1"></a><p></p>
<h3>SPECIAL POPULATIONS</h3>
<div class="Section">
<a name="section-3.1.1.1"></a><p></p>
<h4>Elderly</h4>
<p class="First"><a name="INV-a7af6cfd-4faa-4ce3-a4db-ddd174a9617b"></a>The mean (±SD) elimination half-life of methocarbamol in elderly healthy volunteers (mean (±SD) age, 69 (±4) years) was
													slightly prolonged compared to a younger (mean (±SD) age, 53.3 (±8.8) years), healthy population (1.5 (±0.4) hours versus 1.1 (±0.27) hour, respectively). The fraction of
													bound methocarbamol was slightly decreased in the elderly versus younger volunteers (41 to 43% versus 46 to 50%, respectively).</p>
</div>
<div class="Section">
<a name="section-3.1.1.2"></a><p></p>
<h4>Renally Impaired</h4>
<p class="First"><a name="INV-a1698449-84fa-452a-b9e5-2553f6cd1c65"></a>The clearance of methocarbamol in 8 renally-impaired patients on maintenance hemodialysis was reduced about 40%
													compared to 17 normal subjects, although the mean (±SD) elimination half-life in these two groups was similar (1.2 (±0.6) versus 1.1 (±0.3) hours, respectively).</p>
</div>
<div class="Section">
<a name="section-3.1.1.3"></a><p></p>
<h4>Hepatically Impaired</h4>
<p class="First"><a name="INV-cee04f5c-9145-4bbe-b182-d297ee5bbb3d"></a>In 8 patients with cirrhosis secondary to <span class="product-label-link" type="condition" conceptid="433753" conceptname="Alcohol abuse">alcohol abuse</span>, the mean total clearance of methocarbamol was reduced
													approximately 70% compared to that obtained in 8 age- and weight-matched normal subjects. The mean (±SD) elimination half-life in the cirrhotic patients and the normal
													subjects was 3.38 (±1.62) hours and 1.11 (±0.27) hours respectively. The percent of methocarbamol bound to plasma proteins was decreased to approximately 40 to 45% compared
													to 46 to 50% in the normal subjects.</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="INV-0c94dc00-ebf9-4236-a11c-818e3293d074"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First"><a name="INV-7f9756fa-552d-4aa8-8bd7-4cf6e4ee1c3a"></a>The injectable form of methocarbamol is indicated as an adjunct to rest, physical therapy, and other measures for the relief of
							<span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> associated with acute, painful musculoskeletal conditions. The mode of action of this drug has not been clearly identified, but may be related to its sedative properties.
							Methocarbamol does not directly relax <span class="product-label-link" type="condition" conceptid="4136244" conceptname="Feeling tense">tense</span> skeletal muscles in man.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="INV-132cfa0d-5d23-4f32-bac6-477a420acb3f"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"><a name="INV-d6959e25-9ef7-48b0-85b2-1c51bfe2ddc9"></a>ROBAXIN Injectable should not be administered to patients with known or suspected renal pathology. This caution is necessary
							because of the presence of polyethylene glycol 300 in the vehicle.</p>
<p><a name="INV-2bff586b-fcae-4a1d-a784-975992ae4a2a"></a>A much larger amount of polyethylene glycol 300 than is present in recommended doses of ROBAXIN Injectable is known to have
							increased pre-existing <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span> and urea retention in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Although the amount present in this preparation is well within the limits of safety, caution
							dictates this contraindication.</p>
<p><a name="INV-ca63daca-ca09-4a0e-a651-225ff2fa942a"></a>ROBAXIN Injectable is contraindicated in patients hypersensitive to methocarbamol or to any of the injection
						components.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="INV-2bcc1a94-8d30-480f-9f71-e889a604d41e"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><a name="INV-8a66859d-61dc-4011-b76e-5f19d6e0d6c2"></a>Since methocarbamol may possess a general CNS depressant effect, patients receiving ROBAXIN Injectable should be cautioned about
							combined effects with alcohol and other CNS depressants.</p>
<p><a name="INV-bd1af5b1-7d89-423f-ab6a-fe0635987353"></a>Safe use of ROBAXIN Injectable has not been established with regard to possible adverse effects upon fetal development. There have
							been very rare reports of fetal and congenital abnormalities following in utero exposure to methocarbamol. Therefore, ROBAXIN Injectable should not be used in women who are or may become
							pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards (see <span class="Bold"><a href="#INV-75bfb877-27e2-4332-aae0-a44929b294cf">PRECAUTIONS, Pregnancy</a></span>).</p>
<div class="Section">
<a name="INV-8f4ab6ab-c12a-4d76-a13c-ed0a1ad9ad2d"></a><a name="section-6.1"></a><p></p>
<h2>Use in Activities Requiring Mental Alertness</h2>
<p class="First"><a name="INV-93a8c8e5-6394-4c67-8ee9-d109fe182d4b"></a>Methocarbamol may impair mental and/or physical abilities required for performance of hazardous tasks, such as operating
									machinery or driving a motor vehicle. Patients should be cautioned about operating machinery, including automobiles, until they are reasonably certain that methocarbamol therapy does
									not adversely affect their ability to engage in such activities.</p>
</div>
<div class="Section">
<a name="INV-204d5864-8c9c-40c8-ad74-c2aff8001fb6"></a><a name="section-6.2"></a><p></p>
<h2>Use in Patients with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to Latex</h2>
<p class="First"><a name="INV-c9384dc5-c5e1-4a78-9ed5-0fb275cf38a3"></a>The vial stopper contains dry natural rubber that may cause <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> when handled by or when the product is
									injected in persons with known or possible latex sensitivity.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="INV-c3f79f41-d16a-4668-af36-04a3e7b24e3d"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section">
<a name="INV-43ca0e31-2be1-4618-a41a-b70b7d6dc49d"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First"><a name="INV-fa4d1e1e-6c63-4f90-98a8-00a9f7c47ab0"></a>As with other agents administered either intravenously or intramuscularly, careful supervision of dose and rate of injection
									should be observed. Rate of injection should not exceed 3 mL per minute–i.e., one 10 mL vial in approximately three minutes. Since ROBAXIN Injectable is hypertonic, vascular
									<span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> must be avoided. A recumbent position will reduce the likelihood of side reactions.</p>
<p><a name="INV-c955e67d-aa66-4ad8-aa70-9e6a17827689"></a>Blood aspirated into the syringe does not mix with the hypertonic solution. This phenomenon occurs with many other intravenous
									preparations. The blood may be injected with the methocarbamol, or the injection may be stopped when the plunger reaches the blood, whichever the physician prefers.</p>
<p><a name="INV-89b02b02-f47e-4cea-af6a-8c85874504d7"></a>The total dosage should not exceed 30 mL (three vials) a day for more than three consecutive days except in the treatment of
									<span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span>.</p>
<p><a name="INV-0b44802d-38b9-4ba2-bdda-f33ff0bc01d1"></a>Caution should be observed in using the injectable form in patients with suspected or known <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorders.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="INV-cc08f51a-74ed-47f1-8db7-fcaae7f25cdd"></a><a name="section-7.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First"><a name="INV-102bfec5-8b26-47db-8682-de5d0914bbf4"></a>Patients should be cautioned that methocarbamol may cause <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> or <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, which may impair their ability to operate
									motor vehicles or machinery.</p>
<p><a name="INV-47f55088-1c40-4010-b8d2-5b47bb415806"></a>Because methocarbamol may possess a general CNS-depressant effect, patients should be cautioned about combined effects with
									alcohol and other CNS depressants.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="INV-ebf9afd6-5429-4cab-bdf7-7ce815be13ee"></a><a name="section-7.3"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First"><a name="INV-00b3c005-082b-4668-949f-c2155adf5479"></a>See <span class="Bold"><a href="#INV-8a66859d-61dc-4011-b76e-5f19d6e0d6c2">WARNINGS</a></span> and <span class="Bold"><a href="#INV-fa4d1e1e-6c63-4f90-98a8-00a9f7c47ab0">PRECAUTIONS</a></span> for interaction with CNS drugs and alcohol.</p>
<p><a name="INV-c02416db-e516-449b-8366-6d8400287bf6"></a>Methocarbamol may inhibit the effect of pyridostigmine bromide. Therefore, methocarbamol should be used with caution in
									patients with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> receiving anticholinesterase agents.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="INV-92407856-7551-4632-b858-c9495cc17f3a"></a><a name="section-7.4"></a><p></p>
<h2>Drug and/or Laboratory Test Interactions</h2>
<p class="First"><a name="INV-58e82bd4-fbc1-40f6-b64f-b348c4867008"></a>Methocarbamol may cause a color interference in certain screening tests for 5‑hydroxyindoleacetic acid (5-HIAA) using
									nitrosonaphthol reagent and in screening tests for urinary vanillylmandelic acid (VMA) using the Gitlow method.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="INV-d1ce86bc-bc34-4703-8b4a-b527229e9a13"></a><a name="section-7.5"></a><p></p>
<h2>Carcinogenesis and Mutagenesis and Impairment of Fertility</h2>
<p class="First"><a name="INV-58ac4ee0-6928-435c-a3c4-dd73d7b30a9f"></a>Long-term studies to evaluate the carcinogenic potential of methocarbamol have not been performed. No studies have been
									conducted to assess the effect of methocarbamol on mutagenesis or its potential to impair fertility.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="INV-aeb4720e-9a90-4725-b034-95f56449f8cc"></a><a name="section-7.6"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="INV-07ed5861-c25b-44c2-87d3-4be6faa72050"></a><a name="section-7.6.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<div class="Section">
<a name="section-7.6.1.1"></a><p></p>
<h4>Pregnancy Category C</h4>
<p class="First"><a name="INV-dfd5afd8-67bc-4a16-a66a-22f44ae3857f"></a>Animal reproduction studies have not been conducted with methocarbamol. It is also not known whether methocarbamol can
													cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. ROBAXIN Injectable should be given to a pregnant woman only if clearly needed.</p>
<p><a name="INV-a390cf0a-7d98-4ab1-bc6f-4fa8d211a12d"></a>Safe use of ROBAXIN Injectable has not been established with regard to possible adverse effects upon fetal development.
													There have been reports of fetal and congenital abnormalities following in utero exposure to methocarbamol. Therefore, ROBAXIN Injectable should not be used in women who are
													or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards (see <span class="Bold"><a href="#INV-8a66859d-61dc-4011-b76e-5f19d6e0d6c2">WARNINGS</a></span>).</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="INV-a856bbf5-308f-4052-a6c5-9bae869eebf6"></a><a name="section-7.7"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First"><a name="INV-7f924894-8bbb-4876-b403-906af2159887"></a>Methocarbamol and/or its metabolites are excreted in the milk of dogs; however, it is not known whether methocarbamol or its
									metabolites are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when ROBAXIN Injectable is administered to a nursing
								woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="INV-e76da406-95ed-4f56-bf5d-21ae29acbf8f"></a><a name="section-7.8"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First"><a name="INV-765efc03-90d9-48f8-8ff7-b817e26dd9c3"></a>Safety and effectiveness of ROBAXIN Injectable in pediatric patients have not been established except in <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span>. See <span class="Bold"><a href="#INV-a70c24b2-631b-4963-8ddb-f72c49735c97">DOSAGE AND ADMINISTRATION, Special Directions for Use in
											<span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span></a></span>, For Pediatric Patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="INV-0b4a24b8-7941-4417-90d3-87a93b68c7b0"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"><a name="INV-a41aa396-c0a8-4fcb-8642-e2b64405d552"></a>The following adverse reactions have been reported coincident with the administration of methocarbamol. Some events may have been
							due to an overly rapid rate of intravenous injection.</p>
<div class="Section">
<a name="INV-158fbfd3-b2dd-4a30-91cf-b687adcfcad2"></a><a name="section-8.1"></a><p></p>
<h2>Body as a Whole</h2>
<p class="First"><a name="INV-61b159b2-0486-4df8-9c28-d47ea6a3bb23"></a><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic reaction</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></p>
</div>
<div class="Section">
<a name="INV-93fc2a36-17bf-40da-8fb6-fbcc5aeb471c"></a><a name="section-8.2"></a><p></p>
<h2>Cardiovascular System</h2>
<p class="First"><a name="INV-25b24220-717a-4c76-9700-1e82bae3fdf0"></a><span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span></p>
<p><a name="INV-e3b9312f-f758-4407-8cc4-ff4d501071fb"></a>In most cases of <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> there was spontaneous recovery. In others, epinephrine, injectable steroids, and/or injectable
									antihistamines were employed to hasten recovery.</p>
</div>
<div class="Section">
<a name="INV-d9789080-8df8-46c1-8637-3f7ad46f63c1"></a><a name="section-8.3"></a><p></p>
<h2>Digestive System</h2>
<p class="First"><a name="INV-9be18c27-a9da-4061-a0f0-c3fcf1cb9a54"></a><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> (including <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></p>
</div>
<div class="Section">
<a name="INV-00723630-0d9a-46d6-93bf-5fdb758074ff"></a><a name="section-8.4"></a><p></p>
<h2>Hemic and Lymphatic System</h2>
<p class="First"><a name="INV-c019b7c0-db26-4288-a222-d52e44042652"></a><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span></p>
</div>
<div class="Section">
<a name="INV-5e716f49-0467-4130-a60c-a4d524d92265"></a><a name="section-8.5"></a><p></p>
<h2>Immune System</h2>
<p class="First"><a name="INV-df53e90d-58a4-431e-ad01-242dabfb4ed1"></a><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span></p>
</div>
<div class="Section">
<a name="INV-6289903a-4e7a-4f64-a604-d457121c3e44"></a><a name="section-8.6"></a><p></p>
<h2>Nervous System</h2>
<p class="First"><a name="INV-7a9f0e59-ae60-4021-bcf8-1e935065695c"></a><span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">Amnesia</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or light-headedness, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, mild <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">muscular incoordination</span>, <span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">nystagmus</span>,
									sedation, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> (including <span class="product-label-link" type="condition" conceptid="374924" conceptname="Generalized convulsive epilepsy">grand mal</span>), <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span></p>
<p><a name="INV-f17cb534-9582-4c4e-9e80-2e5e1b00513d"></a>The onset of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsive seizures</span> during intravenous administration of methocarbamol has been reported in patients with <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>
									disorders. The psychic <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span> of the procedure may have been a contributing factor. Although several observers have reported success in terminating epileptiform <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> with ROBAXIN
									Injectable, its administration to patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> is not recommended (see <span class="Bold"><a href="#INV-fa4d1e1e-6c63-4f90-98a8-00a9f7c47ab0">PRECAUTIONS, General</a></span>).</p>
</div>
<div class="Section">
<a name="INV-f59a17c8-e680-4a58-94dc-e41c2c95efa3"></a><a name="section-8.7"></a><p></p>
<h2>Skin and Special Senses</h2>
<p class="First"><a name="INV-1099cb1b-3654-4794-9940-dd64a6a0805a"></a><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Blurred vision</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, metallic taste, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span></p>
</div>
<div class="Section">
<a name="INV-a261799a-122a-4a13-ba9a-597e26ad63e9"></a><a name="section-8.8"></a><p></p>
<h2>Other</h2>
<p class="First"><a name="INV-e29ae2d3-8687-40da-9e99-8d50c77090cf"></a><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> and <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">sloughing</span> at the site of injection</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="INV-d1bd99f2-a51d-4c0a-875e-813069d4955a"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First"><a name="INV-b339d7bf-037e-463b-9a39-87d235b52a79"></a>Limited information is available on the acute toxicity of methocarbamol. <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span> of methocarbamol is frequently in conjunction
							with alcohol or other CNS depressants and includes the following symptoms: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>. In post-marketing experience <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> have
							been reported with an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of methocarbamol alone or in the presence of other CNS depressants, alcohol or psychotropic drugs.</p>
<div class="Section">
<a name="INV-c0594e8a-e464-4514-96d1-5abad4329c31"></a><a name="section-9.1"></a><p></p>
<h2>Treatment</h2>
<p class="First"><a name="INV-d452325d-4b44-4f36-9194-f90fbca9fe2d"></a>Management of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> includes symptomatic and supportive treatment. Supportive measures include maintenance of an adequate
									airway, monitoring urinary output and vital signs, and administration of intravenous fluids if necessary. The usefulness of hemodialysis in managing <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> is unknown.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="INV-3e0772ea-8971-4316-8c9a-7cd614e62c6a"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"><a name="INV-7bfdb6c8-13b9-4721-a1a3-c6c7a855ac7b"></a><span class="Italics">For Intravenous and Intramuscular Use Only. </span>Total adult dosage should not exceed 30 mL (3
							vials) a day for more than 3 consecutive days except in the treatment of <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span>. If the condition persists, a like course may be repeated after a drug-free interval of 48 hours. Dosage
							and frequency of injection should be based on the severity of the condition being treated and therapeutic response noted.</p>
<p><a name="INV-95bd4991-46b2-42d3-a0cb-4382477d242d"></a>For the relief of symptoms of moderate degree, one dose of 1 gram (one 10 mL vial) may be adequate. Ordinarily this injection need
							not be repeated, as the administration of the oral form will usually sustain the relief initiated by the injection. For the severest cases or in postoperative conditions in which oral
							administration is not feasible, additional doses of 1 gram may be repeated every 8 hours up to a maximum of 3 g/day for no more than 3 consecutive days.</p>
<div class="Section">
<a name="INV-f0a2d341-43a9-48b1-9e1f-ab63b2b1b9f7"></a><a name="section-10.1"></a><p></p>
<h2>Directions for Intravenous Use</h2>
<p class="First"><a name="INV-24dee7df-0244-4077-99d2-b537cb98d7f8"></a>ROBAXIN Injectable may be administered undiluted directly into the vein at a <span class="Bold Italics">maximum rate of
										three mL per minute.</span> It may also be added to an intravenous drip of Sodium Chloride Injection (Sterile Isotonic Sodium Chloride Solution for Parenteral Use) or five
									percent Dextrose Injection (Sterile 5 percent Dextrose Solution); one vial given as a single dose should not be diluted to more than 250 mL for I.V. infusion. AFTER MIXING WITH I.V.
									INFUSION FLUIDS, DO NOT REFRIGERATE. Care should be exercised to avoid vascular <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> of this hypertonic solution, which may result in <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>. It is preferable that
									the patient be in a recumbent position during and for at least 10 to 15 minutes following the injection.</p>
</div>
<div class="Section">
<a name="INV-42b034fe-45c8-480f-aac1-a0761400e9b4"></a><a name="section-10.2"></a><p></p>
<h2>Directions for Intramuscular Use</h2>
<p class="First"><a name="INV-99618cd8-66c1-41ef-8577-47f84882f610"></a>When the intramuscular route is indicated, not more than five mL (one-half vial) should be injected into each gluteal region.
									The injections may be repeated at eight hour intervals, if necessary. When satisfactory relief of symptoms is achieved, it can usually be maintained with tablets.</p>
<p><a name="INV-49136e35-8d0c-47cf-81bf-92b9a8a4163c"></a><span class="Italics">Not Recommended for Subcutaneous Administration.</span></p>
</div>
<div class="Section">
<a name="INV-680d0631-59df-4028-8e38-e7886030c047"></a><a name="section-10.3"></a><p></p>
<h2>Special Directions for Use in <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span></h2>
<p class="First"><a name="INV-f9e4a8f6-94e6-4465-8cdd-ffc207c787a9"></a>There is clinical evidence which suggests that methocarbamol may have a beneficial effect in the control of the neuromuscular
									manifestations of <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span>. It does not, however, replace the usual procedure of debridement, <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> antitoxin, penicillin, tracheotomy, attention to fluid balance, and supportive
									care. ROBAXIN Injectable should be added to the regimen as soon as possible.</p>
<div class="Section">
<a name="INV-99e0176e-1e3b-471d-b467-52c19eba092b"></a><a name="section-10.3.1"></a><p></p>
<h3>For Adults</h3>
<p class="First"><a name="INV-0799646d-5426-42b7-a623-91808986a041"></a>Inject one or two vials directly into the tubing of the previously inserted indwelling needle. An additional 10 mL or 20 mL
											may be added to the infusion bottle so that a total of up to 30 mL (three vials) is given as the initial dose (see <span class="Bold"><a href="#INV-fa4d1e1e-6c63-4f90-98a8-00a9f7c47ab0">PRECAUTIONS</a></span>). This procedure should be repeated every six hours until conditions allow for the insertion of a nasogastric tube. Crushed methocarbamol tablets suspended in water or
											saline may then be given through this tube. Total daily oral doses up to 24 grams may be required as judged by patient response.</p>
</div>
<div class="Section">
<a name="INV-3cca35d9-ce71-46fe-a8db-0164ecc991e0"></a><a name="section-10.3.2"></a><p></p>
<h3>For Pediatric Patients</h3>
<p class="First"><a name="INV-a70c24b2-631b-4963-8ddb-f72c49735c97"></a>A minimum initial dose of 15 mg/kg or 500 mg/m<span class="Sup">2</span> is recommended. This dosage may be repeated every six hours, if
											required. The total dose should not exceed 1.8 g/m<span class="Sup">2</span> for 3 consecutive days. The maintenance dosage may be given by injection into tubing or by I.V. infusion with an
											appropriate quantity of fluid. See directions for I.V. use.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="INV-aef729b6-5590-48f7-95df-9540a29f5cda"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"><a name="INV-87ab0038-a024-454d-85b1-ee10711734b5"></a>ROBAXIN Injectable (100 mg/mL) supplied in – 10 mL single dose vials in packages of 25 (NDC 60977-150-01).</p>
<p><a name="INV-219d410d-561e-4764-9564-866977dddf94"></a><span class="Bold">Store at 20</span><span class="Bold">°</span><span class="Bold">- 25</span><span class="Bold">°</span><span class="Bold">C (68</span><span class="Bold">°</span><span class="Bold">- 77</span><span class="Bold">°</span><span class="Bold">F), excursions permitted to 15</span><span class="Bold">°</span><span class="Bold">- 30</span><span class="Bold">°</span><span class="Bold">C (59</span><span class="Bold">°</span><span class="Bold">- 86</span><span class="Bold">°</span><span class="Bold">F).</span></p>
<p><a name="INV-798d6cd4-af7c-445b-b33b-37a1fe96ba42"></a>ROBAXIN is a registered trademark of Wyeth and used under license.</p>
<p><a name="INV-ac1cf588-ea8d-494e-a95c-f16557309b9e"></a>Manufactured by</p>
<p><a name="INV-4ef01b19-306f-4378-8759-d93020a99ff1"></a><span class="Bold">Baxter Healthcare Corporation</span></p>
<p><a name="INV-0da5adb9-2d66-4f25-a6a3-581320513343"></a>Deerfield, IL 60015 USA</p>
<p><a name="INV-c512a8e3-7b79-4ab8-87c3-978037606fbd"></a>For Product Inquiry 1 800 ANA DRUG (1-800-262-3784)</p>
<p><a name="INV-6b99b032-ce5f-4721-a4a7-74534b31c278"></a>MLT-00080/2.0</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ROBAXIN 		
					</strong><br><span class="contentTableReg">methocarbamol injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:60977-150</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR, INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>methocarbamol</strong> (methocarbamol) </td>
<td class="formItem"></td>
<td class="formItem">100 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>polyethylene glycol 300</strong></td>
<td class="formItem">.5 mL  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hydrochloric acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:60977-150-01</td>
<td class="formItem">25  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:60977-150-71</td>
<td class="formItem">10 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Baxter Healthcare Corporation</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 8/2006<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>8f91e243-7395-4ec9-adf5-37520983daf2</div>
<div>Set id: 8f91e243-7395-4ec9-adf5-37520983daf2</div>
<div>Version: 1</div>
<div>Effective Time: 20060818</div>
</div>
</div> <div class="DistributorName">Baxter Healthcare Corporation</div></p>
</body></html>
